Loading company…
Manas AI uses computational chemistry and AI to discover therapeutic candidates for cancer and rare diseases.
Manas AI develops AI and generative computational chemistry tools for drug discovery, focused on oncology and rare diseases including triple-negative breast cancer, prostate cancer, and lymphoma. Its platform uses Microsoft’s Azure cloud infrastructure to support molecular docking and identify therapeutic candidates. Founded in 2025, the company is based in New York and serves pharmaceutical companies and research institutions. In September 2025, it raised USD 26 million in seed funding from The General Partnership, Wisdom Ventures, Blitzscaling Ventures, Westbound, Mosaic Ventures, and other investors.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in